title: Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation.
abstract: BACKGROUND
  We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for non-small cell lung cancer.
  
  
  METHODS
  Clinical records of patients with non-small cell lung cancer who underwent pneumonectomy at our institution between 1995 and 2005 after preoperative concurrent chemoradiation were reviewed retrospectively.
  
  
  RESULTS
  Twenty-nine patients underwent pneumonectomy after preoperative concurrent chemoradiation. Of the 21 men and 8 women who were treated, 1 had stage IIB (T3N0M0) and the remainder had stage IIIA or IIIB non-small cell lung cancer. Mean patient age at surgery was 53.4 years. There were 15 right pneumonectomies, of which 2 were for pancoast tumors. All patients received concurrent preoperative chemoradiation. Mean total radiation dose was 61.1 Gy. All patients went on to have complete (R0) resection by pneumonectomy. Pathologic complete response was found in 16 patients (55.2%). All patients were discharged alive from the hospital after pneumonectomy. Median hospital length of stay was 5 days (mean 8.6). Ninety-day mortality after surgery was 3.4% (n = 1). Recurrences have been found in 11 patients (38%), including brain metastases (n = 6), bone metastases (n = 4), liver metastases (n = 2), and cervical lymph node metastases (n = 2). One patient had a contralateral new primary lung cancer develop 70 months after undergoing pneumonectomy. Estimated 5-year disease-free survival is 48%. Median survival time has not been reached.
  
  
  CONCLUSIONS
  Pneumonectomy can be performed safely after preoperative concurrent chemoradiation, even with high-dose radiation. The frequency of disease recurrence in the brain underscores the need to evaluate the role of prophylactic cranial radiation in non-small cell lung cancer.
authors.affiliation: St. Joseph Cancer Institute, Towson, University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21204, USA. markkrasna@catholichealth.net
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Krasna
authors.forename: Ziv
authors.initials: Z
authors.lastname: Gamliel
authors.forename: Whitney M
authors.initials: WM
authors.lastname: Burrows
authors.forename: Joshua R
authors.initials: JR
authors.lastname: Sonett
authors.forename: King F
authors.initials: KF
authors.lastname: Kwong
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Edelman
authors.forename: Petr F
authors.initials: PF
authors.lastname: Hausner
authors.forename: L Austin
authors.initials: LA
authors.lastname: Doyle
authors.forename: Chad
authors.initials: C
authors.lastname: DeYoung
authors.forename: Mohan
authors.initials: M
authors.lastname: Suntharalingam
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011013:Pneumonectomy / Q000379:methods*; D011829:Radiation Dosage; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents